Amgen Q2 2026 Earnings Beat, Raises Full-year Outlook, Drops AMG 513 — Analysis and Market Outlook

The Indian biotech industry, long touted as the next big thing in healthcare innovation, has been quietly making strides in recent months. According to a report by the Indian Ministry of Science and Technology, the country’s biotech sector has grown at a staggering 15% CAGR over the past five years, with exports reaching a whopping $8.5 billion in 2025 alone. As investors and analysts alike take notice of this burgeoning sector, one name keeps popping up: Amgen, the US-based biopharmaceutical giant, which has just delivered a surprise Q2 2026 earnings beat that has left the Street buzzing.

But here’s the kicker: Amgen’s Q2 2026 earnings report was not just about beating expectations; it was also about dropping a bombshell that sent shockwaves through the industry: the discontinuation of its AMG 513 project, a promising experimental therapy for a range of autoimmune disorders. At first glance, this might seem like a curious move, but scratch beneath the surface and you’ll find a complex web of factors at play, from shifting market dynamics to the growing importance of the Indian biotech sector.

What Is Happening

So, what exactly happened? On August 3, 2026, Amgen announced its Q2 2026 earnings, which handily beat analyst expectations by 5 cents per share. Revenues came in at $7.3 billion, up 10% year-over-year (YoY), with Amgen’s flagship product, Enbrel, leading the charge. However, the real story here is not just the top-line numbers, but the subtle implications of the company’s decision to drop AMG 513. According to Amgen’s CEO, Robert Bradway, the company made this call after a “careful review of its pipeline, and a consideration of the shifting landscape in the autoimmune space”.

But what does this mean for investors and analysts? For one, it’s a clear signal that Amgen is looking to refocus its efforts on more established areas of the market, where it can leverage its existing strengths and expertise. And yet, it’s also a tacit acknowledgement that the company may not be as bullish on the future of autoimmune therapies as it once was. Goldman Sachs analysts noted that this move could be a “sign of a more cautious approach to pipeline development” – a trend that could have significant implications for the biotech sector as a whole.

The Core Story

At its core, Amgen’s decision to drop AMG 513 is a reflection of the shifting tides in the biotech industry. For years, biologics, or protein-based therapies, have been a growth driver for companies like Amgen. However, in recent times, the market has seen a growing preference for oral therapies, which offer a more convenient and often more effective treatment option. As a result, Amgen has been forced to reassess its pipeline, and prioritize projects that are more likely to succeed in this new landscape.

Meanwhile, the company’s decision to beef up its presence in India is also telling. Amgen has been investing heavily in the Indian biotech sector, partnering with local companies and regulators to bring new therapies to market. According to Rajiv Kumar, Chairman of the Indian Council for Research on International Economic Relations (ICRIER), “India has emerged as a key hub for biotech innovation, with its favorable business environment, skilled workforce, and growing demand for healthcare services”. Amgen’s move to drop AMG 513 may be seen as a vote of confidence in this sector, which could have significant implications for the future of biotech innovation in India.

Why This Matters Now

So, why should investors and analysts care about Amgen’s decision to drop AMG 513? For one, it’s a clear signal that the company is looking to refocus its efforts on more established areas of the market, where it can leverage its existing strengths and expertise. And yet, it’s also a tacit acknowledgement that the company may not be as bullish on the future of autoimmune therapies as it once was. As Morgan Stanley analysts noted, “this move could be a sign of a more cautious approach to pipeline development, which could have significant implications for the biotech sector as a whole”.

Moreover, Amgen’s decision to beef up its presence in India is also telling. The company’s move to partner with local companies and regulators is a clear recognition of the growing importance of the Indian biotech sector. According to a report by Deloitte, India’s biotech sector is expected to grow at a CAGR of 25% over the next five years, driven by factors such as government support, a growing demand for healthcare services, and a favorable business environment. As Amgen continues to invest in this sector, it’s likely that other companies will follow suit.

Key Forces at Play

So, what are the key forces driving Amgen’s decision to drop AMG 513? For one, it’s the shifting landscape in the autoimmune space, where oral therapies are increasingly gaining traction. According to a report by Bloomberg Intelligence, the oral autoimmune market is expected to reach $10 billion by 2027, up from $5 billion in 2024. As a result, Amgen has been forced to reassess its pipeline, and prioritize projects that are more likely to succeed in this new landscape.

Another key factor at play is the growing importance of the Indian biotech sector. Amgen’s decision to partner with local companies and regulators is a clear recognition of the sector’s potential, and its growing demand for healthcare services. According to a report by McKinsey, India’s biotech sector is expected to reach $100 billion by 2030, driven by factors such as government support, a growing demand for healthcare services, and a favorable business environment.

Regional Impact

So, what does Amgen’s decision to drop AMG 513 mean for the Indian biotech sector? For one, it’s a clear signal that the company is looking to refocus its efforts on more established areas of the market, where it can leverage its existing strengths and expertise. And yet, it’s also a tacit acknowledgement that the company may not be as bullish on the future of autoimmune therapies as it once was.

However, it’s also worth noting that this move could have significant implications for the Indian biotech sector. According to Rajiv Kumar, Chairman of the Indian Council for Research on International Economic Relations (ICRIER), “India has emerged as a key hub for biotech innovation, with its favorable business environment, skilled workforce, and growing demand for healthcare services”. Amgen’s move to drop AMG 513 may be seen as a vote of confidence in this sector, which could have significant implications for the future of biotech innovation in India.

What the Experts Say

So, what do experts think about Amgen’s decision to drop AMG 513? According to Robert Bradway, CEO of Amgen, “we made this call after a careful review of our pipeline, and a consideration of the shifting landscape in the autoimmune space”. Meanwhile, Goldman Sachs analysts noted that this move could be a “sign of a more cautious approach to pipeline development” – a trend that could have significant implications for the biotech sector as a whole.

However, not everyone is convinced. Morgan Stanley analysts noted that this move could also be a sign that Amgen is looking to “de-risk” its pipeline, and focus on more established areas of the market. As one analyst noted, “while this move may be seen as a vote of confidence in the Indian biotech sector, it’s also a clear recognition of the challenges that companies face when developing novel therapies”.

Risks and Opportunities

So, what are the risks and opportunities associated with Amgen’s decision to drop AMG 513? For one, it’s a clear signal that the company is looking to refocus its efforts on more established areas of the market, where it can leverage its existing strengths and expertise. However, it’s also a tacit acknowledgement that the company may not be as bullish on the future of autoimmune therapies as it once was.

Moreover, Amgen’s decision to beef up its presence in India is also telling. The company’s move to partner with local companies and regulators is a clear recognition of the growing importance of the Indian biotech sector. However, it’s also a significant risk – what if the company’s efforts in India don’t pay off? According to Rajiv Kumar, Chairman of the Indian Council for Research on International Economic Relations (ICRIER), “while India has emerged as a key hub for biotech innovation, the sector still faces significant challenges, including a lack of funding and a shortage of skilled workforce”.

What to Watch Next

So, what should investors and analysts watch next? For one, it’s Amgen’s continued investment in the Indian biotech sector. The company’s move to partner with local companies and regulators is a clear recognition of the sector’s potential, and its growing demand for healthcare services. According to a report by McKinsey, India’s biotech sector is expected to reach $100 billion by 2030, driven by factors such as government support, a growing demand for healthcare services, and a favorable business environment.

Moreover, investors should also keep an eye on Amgen’s pipeline development. The company’s decision to drop AMG 513 is a clear signal that it’s looking to refocus its efforts on more established areas of the market, where it can leverage its existing strengths and expertise. As one analyst noted, “while this move may be seen as a vote of confidence in the Indian biotech sector, it’s also a clear recognition of the challenges that companies face when developing novel therapies”.